N/A N=29 Thymus Transplantation Safety-Efficacy
Complete DiGeorge Anomaly · DiGeorge Syndrome · DiGeorge Anomaly
Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=11 Expanded Access Protocol Thymus Transplantation
Poor Thymic Function · Immunodeficiency · Athymia
Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants
Phase 2 N=14 Phase I/II Thymus Transplantation With Immunosuppression #950
DiGeorge Anomaly · Complete DiGeorge Anomaly · Complete Atypical DiGeorge Anomaly
Primary: Survival at 1 Year Post-CTTI — 71 % of participants who survive to 1 year
Phase 2 N=26 Thymus Transplantation in DiGeorge Syndrome #668
DiGeorge Syndrome · Complete Typical DiGeorge Anomaly
Primary: Survival at 1 Year Post-Cultured Thymus Tissue Implantation (CTTI) — 72 % of participants who survive to 1 year
Phase 2 N=7 Thymus Transplantation Dose in DiGeorge #932
DiGeorge Anomaly · DiGeorge Syndrome · Complete DiGeorge Anomaly
Primary: Survival at 1 Year Post-CTTI — 83 % of participants who survive to 1 year
Phase 2 N=42 Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Non-Hodgkin's Lymphoma · Leukemia · Multiple Myeloma
Primary: The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B…
Phase 2 N=189 Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
COVID-19
Primary: Number of Participants With COVID-19 Infection — 5; 7 participants
N/A N=20 Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Phase 2 N=49 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Thymoma · Thymic Carcinoma · Thymic Carcinoid
Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…
N/A N=44 Low Dose Thymoglobin in Renal Transplant Patients
Acute Renal Failure
Primary: Rates of Acute Cellular Rejection Between Study Group — 4; 2 Number of rejection — p=<0.05
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
Phase 3 N=126 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
Myasthenia Gravis
Primary: Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years — 6.15; 8.99 units on a scale
N/A N=30 Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
Phase 2 N=20 Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
Aplastic Anemia
Primary: Patients Treated With Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) Achieving at Least a Partial Remission (PR) at 6 Months — 9 participants
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
N/A N=200 Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
End Stage Renal Disease
Primary: Treatment Efficacy Will be Defined as the Number of Patients With Biopsy Proven Acute Rejection at One Year Post-transplant. — 6; 10 participants
Phase 2 N=48 Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Myelodysplastic Syndrome · Aplastic Anemia
Primary: Overall Response — 8; 8; 4 participants
Phase 1 N=16 Glutathione and Function in HIV Patients
HIV Infection · Erythrocyte Glutathione Deficiency
Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb
Phase 2 N=47 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Phase 2 N=44 Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras
COVID-19
Primary: Time to Participant Recovery — 6; 12 days
N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Phase 2 N=25 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Phase 2 N=16 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=14 Mechanistic Study of Subclinical Hypothyroidism In the Elderly
Subclinical Hypothyroidism
Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL
Phase 2 N=14 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Phase 2 N=110 A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
Phase 3 N=24 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis · Cough
Primary: Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire. — 47.3; 55.2; 61.6; 44.5 units…
N/A N=206 Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
Thiamine Deficiency · Thiamine Deficiency; Sequelae
Primary: Percentage of Participants With Thiamine Deficiency (Low Plasma Thiamine) Out of Total Number of Enrolled Veterans With Plasma Thiamine Results — 49 Participants